文献速递神经肿瘤

低级别胶质瘤诊断与治疗的基础

Foundations of the Diagnosis and Management of Low-Grade Gliomas.
PubMed 文献 · World Neurosurg · 2022-01-01

低级别胶质瘤为WHO I级和II级肿瘤,但WHO II级弥漫性胶质瘤具有浸润性,手术切除受限,预后可能类似恶性胶质瘤。分子因素尤其是异柠檬酸脱氢酶突变状态和1p/19q共缺失状态比组织学分级更重要,已纳入WHO分类,治疗需个体化。

要点

  • WHO II级弥漫性胶质瘤具有浸润性,手术切除受限,预后可能较差。
  • 异柠檬酸脱氢酶突变状态和1p/19q共缺失状态比分级更能决定预后和治疗反应。
  • 分子特征已纳入WHO胶质瘤分类,治疗需根据分子特征个体化。

核心结论

  • 分子因素尤其是异柠檬酸脱氢酶突变状态和1p/19q共缺失状态比组织学分级更重要,决定预后和治疗反应,管理需个体化。

主要发现

  • WHO II级弥漫性胶质瘤具有浸润性,手术切除受限,可能导致与恶性胶质瘤相似的不良结局。
  • 异柠檬酸脱氢酶突变状态和1p/19q共缺失状态比分级更能决定预后和治疗反应。
  • 分子特征已快速纳入WHO胶质瘤分类,手术、放疗和化疗管理随之转变。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the past, low-grade gliomas-World Health Organization (WHO) grade I and II tumors-were generally expected to have a much better prognosis than higher-grade (WHO grade III and IV) gliomas. However, diffuse gliomas (WHO grade II), unlike WHO grade I gliomas, are by definition infiltrative, limiting resection and potentially contributing to poor outcomes like those seen with malignant gliomas. Rapid progress in the understanding of the pathogenesis of these tumors indicates that specific molecular factors, especially isocitrate dehydrogenase mutation status and the presence or absence of the 1p/19q codeletion (deletion of the short arm of chromosome 1 and long arm of chromosome 19), are much more important than grade in determining prognosis and response to treatment. These molecular characteristics outweigh the histologic distinctions and have been quickly incorporated into the WHO classification of gliomas. Management of these tumors with surgery, radiation, and chemotherapy has similarly been transformed by these developments, highlighting the need for a customized approach for patients with low-grade gliomas.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Norman S, Juthani RG, Magge R, et al. Foundations of the Diagnosis and Management of Low-Grade Gliomas. World Neurosurg. 2022. PMID: 36192862. doi:10.1016/j.wneu.2022.06.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。